| Autor: |
Daniel Bluff, G. Anley, Yein Nam, Afisi S. Ismaila, Leah Sansbury, Robert Wood |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Airway pharmacology and treatment. |
| DOI: |
10.1183/13993003.congress-2020.2426 |
| Popis: |
Background: Previous real-world studies suggest multiple-inhaler triple therapy (MITT; ICS/LAMA/LABA) is overused and incorrectly positioned within the COPD treatment pathway. Addressing the timing of MITT initiation in COPD care to optimise patient outcomes and reduce burdens on healthcare systems is warranted. Objectives: To assess if early MITT initiation in exacerbating patients reduces subsequent healthcare resource utilisation (HCRU), direct medical costs and acute exacerbations of COPD (AECOPDs). Methods: A retrospective, longitudinal cohort study (206974, funded by GlaxoSmithKline plc) using linked electronic medical records and hospital administrative data in the UK. COPD patients were indexed on an AECOPD (Jul 2012–May 2016), followed by MITT initiation within 180 days of indexing. Patients with an AECOPD 6 months prior to indexing were excluded. HCRU, direct medical costs and AECOPDs during 2-year follow-up were compared between early (≤30 days) and delayed (31–180 days) MITT initiators using parametric statistical tests. Results: 11025 COPD patients initiated MITT within 180 days of an AECOPD; 934 met all other selection criteria (367 [39%] early, 567 [61%] delayed). The table shows HCRU, direct medical costs and AECOPDs. Conclusions: Number of inpatient stays and total costs were higher in patients with delayed MITT initiation, suggesting early MITT initiation reduces economic burden on the healthcare system. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
